CollPlant raises $2.6M to fund regenerative medicine push
What's the deal? CollPlant Biotechnologies (Nasdaq: CLGN), an Israeli regenerative and aesthetics medicine company, has signed an agreement for a $2.6 million private placement.
The deal involves selling roughly 7.6 million ordinary shares, plus series A and B warrants, at a combined price of $0.34 per share. H.C. WainwrightDealroom has a profile for this one. Try Dealroom → & Co. is acting as exclusive placement agent.
CollPlant expects the placement to close on or about July 1, 2026.
Why now? The Rehovot-based company plans to use the proceeds for working capital, research and development, and to keep evaluating strategic deals, including acquisitions and joint ventures.
CollPlant develops products based on rhCollagen, a non-animal-derived recombinant human collagen made with its plant-based genetic engineering technology.
What could go wrong? The warrants only become exercisable after shareholder approval, leaving execution dependent on a future vote.
The securities are unregistered and cannot be sold in the US until CollPlant files a resale registration statement with the Securities and Exchange Commission. At $0.34 per share, the modest raise also signals tight financing conditions for the small-cap firm.
The signal: The raise leans on H.C. Wainwright as exclusive placement agent, reflecting how early-stage biotech firms are turning to small private placements to extend their runway amid a tough capital-raising climate. For CollPlant, the modest sum keeps its rhCollagen tissue-regeneration programmes alive while it hunts for larger strategic partnerships.
Read more: PR Newswire
Image credit: CollPlant
